Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis.
Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-alpha (TNF-alpha) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-alpha agents, and periodic monitoring for the development of hepatitis is important.
Ozorio
Gerard
G
Royal Prince Alfred Hospital, Sydney, NSW, Australia. gmoresearch@excite.com
McGarity
Bruce
B
Bak
Haesung
H
Jordan
Andrew S
AS
Lau
Henry
H
Marshall
Cathy
C
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D005260:Female; D019693:Hepatitis, Autoimmune / Q000209:etiology*; D006801:Humans; D000069285:Infliximab; D008099:Liver / Q000473:pathology; D008111:Liver Function Tests; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab